{"paper_id":"c28792e6-32d4-4718-b04e-6ee940afc177","body_text":"Abstarct\nThis chapter discusses primary, secondary, and tertiary prevention in general as well as data on existing options for prevention of endometriosis. Due to unclear etiology of endometriosis and unclear data on possibly modifieable influencing factors such as nutrition, neither causal therapy nor primary prevention are possible yet. Secondary prevention can be achieved by promoting awareness of the disease in the general population and health care professionals as well as specific diagnostic workup including especially a dedicated ultrasonographic exam. Tertiary prevention is achievable by use of postoperative hormonal treatment and complete surgical excision of lesions.\nAccess this chapter\nTax calculation will be finalised at checkout\nPurchases are for personal use only\nSimilar content being viewed by others\nReferences\nSampson JA. Metastatic or embolic endometriosis, due to the menstrual dissemination of endometrial tissue into the venous circulation. Am J Pathol. 1927;3(93–110):143.\nMeyer R. Über den Stand der Frage der Adenomyositis, Adenomyome im Allgemeinen und insbesondere über Adenomyositis seroepithelialis und Adenomyometritis sarcomatosa. Zentralbl Gynäkol. 1919;36:745–50.\nLeyendecker G, Kunz G, Noe M, Herbertz M, Mall G. Endometriosis: a dysfunction and disease of the archimetra. Hum Reprod Update. 1998;4:752–62.\nLeyendecker G, Wildt L, Mall G. The pathophysiology of endometriosis and adenomyosis: tissue injury and repair. Arch Obstet Gynecol Online. 2009;280:529–38.\nGordts S, Koninckx P, Brosens I. Pathogenesis of deep endometriosis. Fertil Steril. 2017;108(872–885):e871.\nKoninckx PR, Ussia A, Adamyan L, Wattiez A, Gomel V, Martin DC. Pathogenesis of endometriosis: the genetic/epigenetic theory. Fertil Steril. 2019;111:327–40.\nParazzini F, Esposito G, Tozzi L, Noli S, Bianchi S. Epidemiology of endometriosis and ist comorbidities. Eur J Obstet Gynecol Reprod Biol. 2017;209:3–7.\nWei M, Cheng Y, Bu H, Zhao Y, Zhao W. Length of menstrual cycle and risk of endometriosis: a meta analysis of 11 case control studies. Medicine. 2016;95:e2922.\nBackonja U, Buck Louis GM, Lauver DR. Overall adiposity, adipose tissue distribution and endometriosis: a systemativ review. Nurs Res. 2016;65:151–66.\nLiu Y, Zhang W. Association between body mass index and endometriosis risk: a metaanalysis. Oncotarget. 2017;8:46928–36.\nBravi F, Parazzini F, Cipriano S, Chiaffarino F, Ricci E, Chiantera V, Vigano P, La Vecchia C. Tobacco smoking and risk of endometriosis: a systematic review and metaanalysis. BMJ Open. 2014;4:e006325.\nChiaffarino F, Bravi F, Cipriano S, Parazzini F, Ricci E, Vigano P, La Vecchia C. Coffee and caffeine intake and risk of endometriosis: a metaaanlysis. Eur J Nutr. 2014;53:1573–9.\nKaracin O, Mutlu I, Kose M, Celik F, Kanat-Pektas M, Yilmazer M. Serum vitamin D concentrations in young Turkish women with primary dysmenorrhea: a randomised controlled study. Taiwanese J Obstet Gynecol. 2018;57:58–63.\nBonocher CM, Montenegro ML, Rosa ESJC, Ferriani RA, Meola J. Endometriosis and physical exercises: a systematic review. Reprod Biol Endocrinol. 2014;12:4.\nBurghaus S, Klingsiek P, Fasching PA, Engel A, Haberle L, Strissel PL, Schmidt M, Jonas K, Strehl JD, Hartmann A, Lehmann J, Boosz A, Thiel FC, Müller A, Beckmann MW, Renner SP. Risk factors for endometriosis in a German case control study. Geburtshilfe Frauenheilkd. 2011;71:1073–9.\nRoy D, Morgan M, Yoo C, Deoraj A, Roy S, Yadav VK, Garoub M, Assaggaf H, Doke M. Integrated bioinformatics, environmental epidemiologic and genomic approaches to identify environmental and molecular links between endometriosis and breast cancer. Int J Mol Sci. 2015;16:25285–322.\nHirsch M, Begum MR, Paniz E, Barker C, Davis CJ, Duffy J. Diagnosis and management of endometriosis: a systematic review of international and national guidelines. BJOG. 2018;125:556–64.\nNagandla K, Idris N, Nalliah S, Sreeramareddy CT, George SRK, Kanagasabai S. Hormonal treatment for uterine adenomyosis. Cochrane Database Syst Rev. 2014; https://doi.org/10.1002/14651858.CD011372.\nBallard K, Lowton K, Wright J. What’s the delay? A qualitativ study of women’s experiences of reaching a diagnosis of endometriosis. Fertil Steril. 2006;86:1296–301.\nHudelist G, Fritzer N, Thomas A, Niehues C, Oppelt P, Haas D, Tammaa A, Salzer H. Diagnostic delay for endometriosis in Austria and Germany: causes and possible consequences. Hum Reprod. 2012;27(12):3412–6.\nGombeski WR Jr, Briller S, Fishleder A, Bat-Cirjak E, Rothner AD, Secic M. Marketing impact of health education programs. J Hosp Mark. 1997;11(2):91–103.\nBush D, Brick E, East MC, Johnson N. Endometriosis education in schools: a New Zealand model examining the impact of an education program in schools on early recognition of symptoms suggesting endometriosis. Aust N Z J Obstet Gynecol. 2017;57:452–7.\nVan der Zanden M, Nap AW. Knowledge of, and treatment strategies for, endometriosis among general practitioners. Reprod Biomed Online. 2016;32:527–31.\nRicci G, Castelpietra E, Romano F, Di Lorenzo G, Zito G, Ronfani L, Biffi S, Monasta L. Case-control study to develop and validate a questionnaire fort he secondary prevention of endometriosis. PLoS One. 2020;15(3):e0230828.\nGuerriero S, Condous G, Van den Bosch T, Valentin L, Leone FPG, Van Schoubroeck D, Exacoustos C, Installé AJF, Martins WP, Abrao MS, Hudelist G, Bazot M, Alcazar JL, Goncalves MO, Pascual MA, Ajossa S, Savelli L, Dunham R, Reid S, Menakaya U, Bourne T, Ferrero S, Leon M, Bignardi T, Holland T, Jurkovic D, Benacerraf B, Osuga Y, Somigliana E, Timmerman D. Systematic approach to sonographic evaluation of the pelvis in women with suspected endometriosis, including terms, definitions and measurements: a consensus opinion from the International Deep Endometriosis Analysis (IDEA) group. Ultrasound Obstet Gynecol. 2016;48:318–32.\nLi Q, Ding Y, Zhang XY, Feng WW, Hua KQ. Drug therapy for adenomyosis: a prospective, nonrandomized, parallel controlled study. J Int Med Res. 2018;46:1855–65.\nFerrero S, Barra F, Leone Roberti Maggiore U. Current and emerging therapeutics for the management of endometriosis. Drugs. 2018:1–18. https://doi.org/10.1007/s40265-018-0928-0.\nStrowitzki T, Faustmann T, Gerlinger C, Schumacher U, Ahlers C, Seitz C. Safety and tolerabilits of dienogest in endometriosis: pooled analysis from the European clinical study program. Int J Women's Health. 2015;7:393–401.\nZheng Q, Mao H, Xu Y, Zhao J, Wei X, Liu P. Can postoperative GnRH agonist treatment prevent endometriosis recurrence? A meta-analysis. Arch Gyn Obstet. 2016;294:201–7.\nWu D, Hu M, Hong L, Hong S, Ding W, Min J, Fang G, Guo W. Clinical efficacy of add back therapy in treatment of endometriosis: a meta analysis. Arch Gyn Obstet. 2014;290:513–23.\nLee DY, Lee JY, Seo JW, Yoon BK, Choi DS. Gonadotropin-releasing hormone agonist with add back treatment is as effective and tolerable as dienogest in preventing pain recurrence after laparoscopic surgery for endometriosis. Arch Gyn Obstet. 2016;294:1257–63.\nDi Vasta AD, Feldman HA, Sadler Gallagher J, Stokes NA, Laufer MR, Hornstein MD, Gordon CM. Hormonal add back therapy for females treated with gonadotropin releasing hormone agonist for endometriosis. Obstet Gynecol. 2015;126:617–27.\nCasper CF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil Steril. 2017;107:533–6.\nEdelman A, Micks E, Gallo MF, Jensen JT, Grimes DA. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev. 2014; https://doi.org/10.1002/14651858.CD004695. pub3: Cd004695\nJensen JT, Schlaff W, Gordon K. Use of combined oral contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence. Fertil Steril. 2018;110:137–152.e131.\nMuzii L, Di Tucci C, Achilli C, Di Donato V, Musella A, Palaia I, Panici PB. Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis. AJOG. 2016;214:203–11.\nGrandi G, Xholli A, Napolitano A, Palma F, Cagnacci A. Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate/dienogest oral contraceptive: a patient preference prospective 24-week pilot study. Reprod Sci. 2015;22:626–32.\nZorbas KA, Economopoulos KP, Vlahos NF. Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review. Arch Gynecol Obstet. 2015;292:37–43.\nAdachi K, Takahashi K, Nakamura K, Otake A, Sasamoto N, Miyoshi Y, Shioji M, Yamamoto Y, Fujitani M, Wakimoto A, Tokuhira A, Kobayashi E, Yoshimura A, Sawada K, Kimura T. Postoperative administration of dienogest for suppressing recurrence of disease and relieving pain in subjects with ovarian endometriomas. Gynecol Endocrinol. 2016;32:646–9.\nLee N, Seunggi M, Seyeon W, Yeon Jean C, Miseon K, Mi Kyoung K, Yong Wook J, Bo Seong Y, Seok JS, Mi-La K. The recurrence rate of ovarian endometrioma in women aged 40 – 49 years and impact of hormonal treatment after conservative surgery. Sci Reports. 2020;10:16461.\nZakhari A, Delpero E, McKeown S, Tomlinson G, Bougie O, Murji A. Endometriosis recurrence following post-operative hormonal suppression: a systematic review and meta-analysis. Hum Reprod Update. 2020:1–12. https://doi.org/10.1093/humupd/dmaa033.\nLee KH, Jung YW, Song SY, Kang BH, Yang JB, Ko YB, Lee M, Han HY, Yoo HJ. Comparison of the efficacy of dienogest and levonorgestrel-releasing intrauterine system after laparoscopic surgery for endometriosis. J Obstet Gynecol Res. 2018; https://doi.org/10.1111/jog.13703.\nBozdag G. Recurrence of endometriosis: risk factors, mechanisms and biomarkers. Womens Health. 2015;11(5):693–9.\nIwase A, Nakamura T, Nakahara T, Goto M, Kikkawa F. Assessment of ovarian reserve using anti-Mullerian hormone levels in benign gynecologic conditions and surgical interventions: a systematic narrative review. Reprod Biol Endocrinol. 2014;12:125.\nDeckers P, Ribeiro SC, Simoes RDS, Miyahara C, Baracat EC. Systematic review and metaanalysis of the effect of bipolar electrocoagulation during laparoscopic ovarian endometrioma stripping on ovarian reserve. Int J Gynecol. 2018;140:11–7.\nMoscarini M, Milazzo GN, Assorgi C, Pacchiarotti A, Caserta D. Ovarian stripping versus cystectomy: recurrence of endometriosis and pregnancy rate. Arch Gynecol Obstet. 2014;290:163–1.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEditor information\nEditors and Affiliations\nRights and permissions\nCopyright information\n© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG\nAbout this chapter\nCite this chapter\nSchäfer, S.D. (2022). Prevention of Endometriosis: Is It Possible?. In: Oral, E. (eds) Endometriosis and Adenomyosis. Springer, Cham. https://doi.org/10.1007/978-3-030-97236-3_27\nDownload citation\nDOI: https://doi.org/10.1007/978-3-030-97236-3_27\nPublished:\nPublisher Name: Springer, Cham\nPrint ISBN: 978-3-030-97235-6\nOnline ISBN: 978-3-030-97236-3\neBook Packages: MedicineMedicine (R0)","source_license":"CC0","license_restricted":false}